Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 9, 2014, Pages 1428-1436

  Levi, M ^a   Moore, K T ^b   Castillejos, C F ^b   Kubitza, D ^c   Berkowitz, S D ^d   Goldhaber, S Z ^e   Raghoebar, M ^f   Patel, M R ^g   Weitz, J I ^h   Levy, J H ^g  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c BAYER PHARMA AG   (Germany)

^d BAYER CORPORATION   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h MCMASTER UNIVERSITY   (Canada)

Author keywords

Anticoagulants; Hemorrhage; Pharmacology; Prothrombin complex concentrates; Rivaroxaban

Indexed keywords

PROTHROMBIN; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 9; RIVAROXABAN; SODIUM CHLORIDE; THROMBIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; DRUG COMBINATION; FACTOR IX, FACTOR VII, FACTOR X, PROTHROMBIN DRUG COMBINATION; MORPHOLINE DERIVATIVE; PROTHROMBIN COMPLEX CONCENTRATES; THIOPHENE DERIVATIVE;

ABDOMINAL DISCOMFORT; ADULT; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; BACKACHE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; GINGIVA BLEEDING; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MORNING DOSAGE; NORMAL HUMAN; OPEN STUDY; PARALLEL DESIGN; PHARMACODYNAMICS; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; THROMBIN TIME; TIME TO MAXIMUM PLASMA CONCENTRATION; ADOLESCENT; BODY MASS; CHEMISTRY; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; HEMORRHAGE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTICOAGULANTS; AREA UNDER CURVE; BLOOD COAGULATION FACTORS; BODY MASS INDEX; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FACTOR IX; FACTOR VII; FACTOR X; FEMALE; HEALTHY VOLUNTEERS; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN; PROTHROMBIN TIME; THIOPHENES; THROMBIN; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84908502375     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12599     Document Type: Article

References (19)

1. Bayer Pharma AG. Xarelto® (rivaroxaban) Summary of Product Characteristics. 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf. Accessed 10 June 2013.
2. Mavrakanas T, Bounameaux H. The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism. Pharmacol Ther 2011; 130: 46-58.
3. Ng HJ, Crowther MA. New anti-thrombotic agents: emphasis on hemorrhagic complications and their management. Semin Hematol 2006; 43: S77-83.
4. Sarode R, Milling TJ Jr, Refaai MA, Mangione A, Schneider A, Durn BL, Goldstein JN. Efficacy and safety of a four-factor pro- thrombin complex concentrate (4F-PCC) in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation 2013; 128:1234-43.
5. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebocontrolled, crossover study in healthy subjects. Circulation 2011; 124: 1573-9.
6. Godier A, Miclot A, Le Bonniec B, Durand M, Fischer AM, Emmerich J, Marchand-Leroux C, Lecompte T, Samama CM. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 2012; 116: 94-102.
7. Perzborn E, Trabandt A, Selbach K, Tinel H. Prothrombin complex concentrate reverses the effects of high-dose rivaroxaban in rats. Pathophysiol Haemost Thromb 2010; 37: A10-OC251.
8. Abe T, Kazama M. An International Survey on the Appropriate Dosage of Hemophilias and Related Congenital Coagulopathies. Proceedings of the 3rd International Symposium on Haemostasis and Thrombosis 1982: 273-304.
9. Baxter Healthcare Corporation. Bebulin Prescribing Information. 2013. Available at: http://www.baxter.com/healthcare_professionals/products/bebulin_vh.html. Accessed 3 April 2013.
10. Nilsson IM, Ahlberg A, Bjorlin G. Clinical experience with a Swedish factor IX concentrate. Acta Med Scand 1971; 190: 257-66.
11. Rizza CR, Jones P. Management of patients with inherited blood coagulation defects. In: Bloom AL, ed. Hemostasis and Thrombosis. Edingburgh: Churchill Livingstone, 1987: 465-93.
12. Rohde G. Determination of rivaroxaban - a novel, oral, direct factor Xa inhibitor - in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 872: 43-50.
13. Franchini M, Lippi G. Prothrombin complex concentrates: an update. Blood Transfus 2010; 8: 149-54.
14. Schulman S, Bijsterveld NR. Anticoagulants and their reversal. Transfus Med Rev 2007; 21: 37-48.
15. Bijsterveld NR, Moons AH, Boekholdt SM, van Aken BE, Fennema H, Peters RJ, Meijers JC, Buller HR, Levi M. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002; 106: 2550-4.
16. Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 108: 217-24.
17. Elg M, Carlsson S, Gustafsson D. Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits. Thromb Res 2001; 101: 159-70.
18. Elg M, Carlsson S, Gustafsson D. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. Thromb Res 2001; 101:145-57.
19. Skolnick BE, Mathews DR, Khutoryansky NM, Pusateri AE, Carr ME. Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects. Blood 2010; 116: 693-701.